Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02007512
What this trial is testing

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 247
Not applicableStudy completedNCT06363812
What this trial is testing

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 258
Testing effectiveness (Phase 2)Study completedNCT02756364
What this trial is testing

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Who this might be right for
Breast Neoplasms
Calithera Biosciences, Inc 141
Testing effectiveness (Phase 2)Study completedNCT00856492
What this trial is testing

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 215
Early research (Phase 1)Study completedNCT04647487
What this trial is testing

LY3484356 in Women With Breast Cancer Before Having Surgery

Who this might be right for
Breast Cancer
Eli Lilly and Company 87
Testing effectiveness (Phase 2)Study completedNCT02860000
What this trial is testing

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Who this might be right for
Estrogen Receptor StatusHER2/Neu NegativeInvasive Breast Carcinoma+6 more
Mayo Clinic 96
Early research (Phase 1)Active Not RecruitingNCT02204098
What this trial is testing

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Who this might be right for
Breast CancerBreast CarcinomaMalignant Neoplasm of Breast
Washington University School of Medicine 27
Testing effectiveness (Phase 2)WithdrawnNCT06710197
What this trial is testing

IL-1 Inhibition in Early TNBC

Who this might be right for
Early Stage Triple Negative ER Low Breast Cancer
University Health Network, Toronto
Testing effectiveness (Phase 2)Ended earlyNCT02395627
What this trial is testing

Reversing Therapy Resistance With Epigenetic-Immune Modification

Who this might be right for
Breast Neoplasms
University of California, San Francisco 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT05296746
What this trial is testing

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Who this might be right for
Breast Cancer Stage II
SOLTI Breast Cancer Research Group 1,100
Large-scale testing (Phase 3)UnknownNCT03351062
What this trial is testing

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Who this might be right for
Breast Cancer Female
Chinese Anti-Cancer Association 844
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Testing effectiveness (Phase 2)Looking for participantsNCT06167694
What this trial is testing

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Who this might be right for
Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd. 146
Testing effectiveness (Phase 2)Study completedNCT01575522
What this trial is testing

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
National Cancer Institute (NCI) 22
Not applicableUnknownNCT06544577
What this trial is testing

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Who this might be right for
ESR1 Gene MutationAdvanced Breast CancerSafety
SciClone Pharmaceuticals 350
Testing effectiveness (Phase 2)Looking for participantsNCT06450873
What this trial is testing

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic 40
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Not applicableStudy completedNCT01298362
What this trial is testing

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

Who this might be right for
Breast CancerOther Disorders of Bone Density and Structure
Hellenic Breast Surgeons Society 290
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Next Page